MEXICO CITY, Jan. 5, 2024 /PRNewswire/ — Grupo Aeromexico S.A.B. de C.V. (“Aeromexico”) reports its December 2023 operational results: Grupo Aeromexico transported 2 million and 206 thousand passengers in December 2023, a 4.3% year-on-year increase. International passengers increased by 20.6%, while domestic passengers decreased by 2.4%. Aeromexico’s total capacity, measured in available seat kilometers (ASKs),… Continue reading Aeromexico December 2023 Traffic Results
Category: Newswire
DG Investors Have Opportunity to Lead Dollar General Corporation Securities Fraud Lawsuit
LOS ANGELES, Jan. 5, 2024 /PRNewswire/ — The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Dollar General Corporation (“Dollar General” or the “Company”) (NYSE: DG). Class Period: February 23, 2023 – August 31, 2023 Lead Plaintiff Deadline: January 26,… Continue reading DG Investors Have Opportunity to Lead Dollar General Corporation Securities Fraud Lawsuit
NATI Investors Have Opportunity to Lead National Instruments Corporation Securities Fraud Lawsuit
LOS ANGELES, Jan. 5, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against National Instruments Corporation (“National Instruments” or the “Company”) (NASDAQ: NATI). Class Period: May 25, 2022 – January 17, 2023 Lead Plaintiff Deadline: January 29, 2024… Continue reading NATI Investors Have Opportunity to Lead National Instruments Corporation Securities Fraud Lawsuit
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass., Jan. 5, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2024 the Company granted inducement awards to purchase up to 8,600 shares of common stock to one new employee under the Company’s 2023 Inducement Plan. The stock options… Continue reading Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Trinity Capital Inc. Appoints Michael Testa as Chief Financial Officer
PHOENIX, Jan. 5, 2024 /PRNewswire/ — Trinity Capital Inc. (Nasdaq: TRIN) (“Trinity,” “Trinity Capital” or the “Company”), a leading provider of diversified financial solutions to growth-stage companies, today announced that, as part of the Company’s long-term succession plan, its Board of Directors has named Michael Testa as Chief Financial Officer (“CFO”), effective immediately. He succeeds David… Continue reading Trinity Capital Inc. Appoints Michael Testa as Chief Financial Officer
Gibson Energy Announces Director Resignation
CALGARY, AB, Jan. 5, 2024 /PRNewswire/ – Gibson Energy Inc. (“Gibson” or the “Company”) announced today that John Festival has resigned from its Board of Directors, effective immediately, in order to focus on his increasing professional commitments. John Festival was appointed a Director of Gibson in 2018 and served as a member of both the… Continue reading Gibson Energy Announces Director Resignation
JRVR Investors Have Opportunity to Lead James River Group Holdings, Ltd. Securities Fraud Lawsuit
BENSALEM, Pa., Jan. 5, 2024 /PRNewswire/ — Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR). Class Period: August 7, 2023 – November 7, 2023 Lead Plaintiff Deadline: January 12,… Continue reading JRVR Investors Have Opportunity to Lead James River Group Holdings, Ltd. Securities Fraud Lawsuit
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ — Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective January 1, 2023, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 9,393 shares of its common stock and an aggregate of 4,696 restricted stock units (RSUs) to two new… Continue reading Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EXFY Investors Have Opportunity to Lead Expensify, Inc. Securities Fraud Lawsuit
BENSALEM, Pa., Jan. 5, 2024 /PRNewswire/ — Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Expensify, Inc. (“Expensify” or the “Company”) (NASDAQ: EXFY). Class Period: November 2021 IPO Lead Plaintiff Deadline: January 29, 2024 Investors suffering losses on their Expensify… Continue reading EXFY Investors Have Opportunity to Lead Expensify, Inc. Securities Fraud Lawsuit
LPSN Investors Have Opportunity to Lead LivePerson, Inc. Securities Fraud Lawsuit
LOS ANGELES, Jan. 5, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against LivePerson, Inc. (“LivePerson” or the “Company”) (NASDAQ: LPSN). Class Period: May 10, 2022 – March 16, 2023 Lead Plaintiff Deadline: January 30, 2024 If you wish… Continue reading LPSN Investors Have Opportunity to Lead LivePerson, Inc. Securities Fraud Lawsuit